Literature DB >> 24913807

Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.

Chien-Hung Gow1, Shang-Gin Wu, Yih-Leong Chang, Jin-Yuan Shih.   

Abstract

Several new chromosomal translocations resulting in driver fusion mutations have recently been discovered in non-small-cell lung cancer. The driver mutational patterns in pulmonary mucinous adenocarcinoma, a rare subtype of non-small-cell lung cancer, have not been well studied. A single-institute cohort study in Taiwan was performed to determine the mutations of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), fusions of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and neuregulin 1 (NRG1) in patients diagnosed with pulmonary mucinous adenocarcinoma. We also examined NRG1 translocation in patients diagnosed as adenocarcinoma of other subtypes with wild-type EGFR, KRAS, ALK, and ROS1 genes. Surgical or biopsy specimens were collected from 13 patients with mucinous adenocarcinoma. Using the direct RNA sequencing method, we discovered a rare CD74-NRG1 fusion (8 %), an echinoderm microtubule-associated protein like 4 (EML4)-ALK fusion (17 %), and three KRAS mutations (25 %). No EGFR mutations or ROS1 rearrangements were detected. The rare CD74-NRG1 fusion positive patient presented with uncommon radiological features. We did not detect any CD74-NRG1 fusion in the 109 adenocarcinoma of other subtypes, which were all negative for EGFR, KRAS, ALK, and ROS1. The CD74-NRG1 fusion mutation is rare and may be exclusively present in patients with pulmonary mucinous adenocarcinoma. Patients harboring CD74-NRG1 positive tumors may present with uncommon imaging features.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24913807     DOI: 10.1007/s12032-014-0034-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

2.  Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.

Authors:  Hideomi Ichinokawa; Genichiro Ishii; Kanji Nagai; Akikazu Kawase; Junji Yoshida; Mitsuyo Nishimura; Tomoyuki Hishida; Naomi Ogasawara; Katsuya Tsuchihara; Atsushi Ochiai
Journal:  Hum Pathol       Date:  2013-10-10       Impact factor: 3.466

3.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim Geisinger; Yasushi Yatabe; Charles A Powell; David Beer; Greg Riely; Kavita Garg; John H M Austin; Valerie W Rusch; Fred R Hirsch; James Jett; Pan-Chyr Yang; Michael Gould
Journal:  Proc Am Thorac Soc       Date:  2011-09

4.  Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.

Authors:  Akito Hata; Nobuyuki Katakami; Shiro Fujita; Reiko Kaji; Yukihiro Imai; Yutaka Takahashi; Takashi Nishimura; Keisuke Tomii; Kyosuke Ishihara
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

5.  Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.

Authors:  Hang Li; Yunjian Pan; Yuan Li; Chenguang Li; Rui Wang; Haichuan Hu; Yang Zhang; Ting Ye; Lei Wang; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Lung Cancer       Date:  2012-10-23       Impact factor: 5.705

6.  Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.

Authors:  Issan Yee San Tam; Lap Ping Chung; Wai Sing Suen; Elaine Wang; May C M Wong; Kok Keung Ho; Wah Kit Lam; Shui Wah Chiu; Luc Girard; John D Minna; Adi F Gazdar; Maria P Wong
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

7.  Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.

Authors:  S-G Wu; C-H Gow; C-J Yu; Y-L Chang; C-H Yang; Y-C Hsu; J-Y Shih; Y-C Lee; P-C Yang
Journal:  Eur Respir J       Date:  2008-05-28       Impact factor: 16.671

8.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

9.  ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.

Authors:  Yuan Li; Yunjian Pan; Rui Wang; Yihua Sun; Haichuan Hu; Xuxia Shen; Yongming Lu; Lei Shen; Xiongzeng Zhu; Haiquan Chen
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

View more
  8 in total

Review 1.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

2.  Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.

Authors:  Saravana M Dhanasekaran; O Alejandro Balbin; Guoan Chen; Ernest Nadal; Shanker Kalyana-Sundaram; Jincheng Pan; Brendan Veeneman; Xuhong Cao; Rohit Malik; Pankaj Vats; Rui Wang; Stephanie Huang; Jinjie Zhong; Xiaojun Jing; Matthew Iyer; Yi-Mi Wu; Paul W Harms; Jules Lin; Rishindra Reddy; Christine Brennan; Nallasivam Palanisamy; Andrew C Chang; Anna Truini; Mauro Truini; Dan R Robinson; David G Beer; Arul M Chinnaiyan
Journal:  Nat Commun       Date:  2014-12-22       Impact factor: 14.919

3.  Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.

Authors:  Domenico Trombetta; Paolo Graziano; Aldo Scarpa; Angelo Sparaneo; Giulio Rossi; Antonio Rossi; Massimo Di Maio; Davide Antonello; Andrea Mafficini; Federico Pio Fabrizio; Maria Carmina Manzorra; Teresa Balsamo; Flavia Centra; Michele Simbolo; Angela Pantalone; Michela Notarangelo; Paola Parente; Maria Cecilia Lucia Dimitri; Antonio Bonfitto; Fabiola Fiordelisi; Clelia Tiziana Storlazzi; Alberto L'Abbate; Marco Taurchini; Evaristo Maiello; Vito Michele Fazio; Lucia Anna Muscarella
Journal:  Oncotarget       Date:  2018-01-03

4.  NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.

Authors:  Michaël Duruisseaux; Anne McLeer-Florin; Martine Antoine; Sanaz Alavizadeh; Virginie Poulot; Roger Lacave; Nathalie Rabbe; Jacques Cadranel; Marie Wislez
Journal:  Cancer Med       Date:  2016-10-21       Impact factor: 4.452

5.  Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.

Authors:  Lei Cai; Jiangfeng Wang; Junrong Yan; Jian Zeng; Liang Zhu; Jinxiao Liang; Chao Pan; Xiancong Huang; Ju Jin; Yang Xu; Fufeng Wang; Yang Shao; Qinqin Xu; Guojie Xia; Minyan Xing; Xiaoling Xu; Youhua Jiang
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

Review 6.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 7.  NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

Authors:  J Laskin; S V Liu; K Tolba; C Heining; R F Schlenk; P Cheema; J Cadranel; M R Jones; A Drilon; A Cseh; S Gyorffy; F Solca; M Duruisseaux
Journal:  Ann Oncol       Date:  2020-09-09       Impact factor: 51.769

8.  Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.

Authors:  Dong Hoon Shin; Donghoon Lee; Dong Wan Hong; Seung Hyun Hong; Jung-Ah Hwang; Byung Il Lee; Hye Jin You; Geon Kook Lee; In-Hoo Kim; Yeon-Su Lee; Ji-Youn Han
Journal:  Oncotarget       Date:  2016-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.